Fanizzi Fabrizio, D'Amico Ferdinando, Zanotelli Bombassaro Isadora, Zilli Alessandra, Furfaro Federica, Parigi Tommaso Lorenzo, Cicerone Clelia, Fiorino Gionata, Peyrin-Biroulet Laurent, Danese Silvio, Allocca Mariangela
Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Department of Gastroenterology and Endoscopy, Santa Casa de Misericordia de Porto Alagre, Porto Alegre 90020-090, Brazil.
Microorganisms. 2024 Aug 23;12(9):1755. doi: 10.3390/microorganisms12091755.
Gut microbiota dysbiosis has a critical role in the pathogenesis of inflammatory bowel diseases, prompting the exploration of novel therapeutic approaches like fecal microbiota transplantation, which involves the transfer of fecal microbiota from a healthy donor to a recipient with the aim of restoring a balanced microbial community and attenuating inflammation. Fecal microbiota transplantation may exert beneficial effects in inflammatory bowel disease through modulation of immune responses, restoration of mucosal barrier integrity, and alteration of microbial metabolites. It could alter disease course and prevent flares, although long-term durability and safety data are lacking. This review provides a summary of current evidence on fecal microbiota transplantation in inflammatory bowel disease management, focusing on its challenges, such as variability in donor selection criteria, standardization of transplant protocols, and long-term outcomes post-transplantation.
肠道微生物群失调在炎症性肠病的发病机制中起关键作用，促使人们探索如粪便微生物群移植等新型治疗方法，粪便微生物群移植是将健康供体的粪便微生物群转移到受体，目的是恢复微生物群落平衡并减轻炎症。粪便微生物群移植可能通过调节免疫反应、恢复黏膜屏障完整性和改变微生物代谢产物在炎症性肠病中发挥有益作用。尽管缺乏长期疗效和安全性数据，但它可能改变疾病进程并预防病情发作。本综述总结了目前关于粪便微生物群移植用于炎症性肠病管理的证据，重点关注其面临的挑战，如供体选择标准的差异、移植方案的标准化以及移植后的长期结果。
